Tocagen’s initial proposed indication, recurrent high grade glioma, or HGG, is the most common and aggressive primary brain cancer. The two most common forms of HGG are glioblastoma and anaplastic astrocytoma. HGG recurs in most patients, even after maximal treatment. Participation in a clinical trial is one possible option for people who have regrowth of these types of brain cancers. It is recommended that patients talk with their doctor to discuss potential participation in a clinical trial.
Tocagen is conducting a Phase 2/3 clinical trial, called Toca 5, for patients with recurrent HGG. Enrollment of the Phase 2 portion was completed in February 2017 and Tocagen plans to report top line results in the first half of 2018.